ATE417066T1 - Modifizierte cdna für hohe expressionsniveaus von faktor viii und dessen derivaten - Google Patents

Modifizierte cdna für hohe expressionsniveaus von faktor viii und dessen derivaten

Info

Publication number
ATE417066T1
ATE417066T1 AT04790326T AT04790326T ATE417066T1 AT E417066 T1 ATE417066 T1 AT E417066T1 AT 04790326 T AT04790326 T AT 04790326T AT 04790326 T AT04790326 T AT 04790326T AT E417066 T1 ATE417066 T1 AT E417066T1
Authority
AT
Austria
Prior art keywords
derivatives
factor viii
dna sequences
expression vectors
expression levels
Prior art date
Application number
AT04790326T
Other languages
English (en)
Inventor
Hans-Peter Hauser
Jean-Luc Plantier
Cecille Ducasse
Claude Negrier
Original Assignee
Claude Negrier
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Claude Negrier filed Critical Claude Negrier
Application granted granted Critical
Publication of ATE417066T1 publication Critical patent/ATE417066T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT04790326T 2003-10-16 2004-10-13 Modifizierte cdna für hohe expressionsniveaus von faktor viii und dessen derivaten ATE417066T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP03023637 2003-10-16

Publications (1)

Publication Number Publication Date
ATE417066T1 true ATE417066T1 (de) 2008-12-15

Family

ID=34486073

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04790326T ATE417066T1 (de) 2003-10-16 2004-10-13 Modifizierte cdna für hohe expressionsniveaus von faktor viii und dessen derivaten

Country Status (15)

Country Link
US (1) US20080312143A1 (de)
EP (1) EP1673391B1 (de)
JP (1) JP4804356B2 (de)
AT (1) ATE417066T1 (de)
AU (1) AU2004283833A1 (de)
BR (1) BRPI0415296A (de)
CA (1) CA2541280A1 (de)
DE (1) DE602004018349D1 (de)
DK (1) DK1673391T3 (de)
ES (1) ES2319198T3 (de)
IL (1) IL174645A0 (de)
PL (1) PL1673391T3 (de)
PT (1) PT1673391E (de)
SI (1) SI1673391T1 (de)
WO (1) WO2005040213A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2543629T3 (es) 2006-05-17 2015-08-20 Hoffmann-La Roche Ag Células productoras de polipéptidos
FR2913020B1 (fr) 2007-02-23 2012-11-23 Biomethodes Nouveaux facteurs viii pour le traitement des hemophiles de type a
EP3452102B9 (de) 2016-04-15 2024-09-04 The Trustees of The University of Pennsylvania Gentherapie zur behandlung von hämophilie a
JP6818134B2 (ja) 2016-09-29 2021-01-20 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ポリペプチド産生細胞を選択するための改善された方法
CN109507435A (zh) * 2018-11-23 2019-03-22 重庆医科大学 Grp78蛋白双抗夹心elisa法检测试剂盒及其检测方法
GB202108855D0 (en) * 2021-06-21 2021-08-04 Cambridge Entpr Ltd Methods of eukaryotic gene expression

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2197321B (en) * 1986-09-12 1990-10-03 Genentech Inc Method and vectors for obtaining continuous production of heterologous protein in a eukaryotic host cell line
DK0874057T3 (da) * 1993-06-10 2004-11-22 Bayer Ag Vektor og pattedyrcellelinie med forbedret produktionsevne
EP1048726B1 (de) * 1999-04-27 2006-07-26 Négrier, Claude Modifizierte Faktor VIII cDNA
EP1038959A1 (de) * 1999-03-17 2000-09-27 Aventis Behring Gesellschaft mit beschränkter Haftung Faktor VIII ohne B-Domän, der ein oder mehrere Insertionsstücke von verkürztem Intron I des Faktors IX enthält
EP1233064A1 (de) * 2001-02-09 2002-08-21 Aventis Behring Gesellschaft mit beschränkter Haftung Modifizierte Faktor VIII cDNA und deren Verwendung bei der Produktion von Faktor VIII
EP1283263A1 (de) * 2001-08-08 2003-02-12 Aventis Behring GmbH Modifizierte cDNA für die erhöhte Expression von Faktor VIII und seinen Derivaten
EP1284290A1 (de) * 2001-08-08 2003-02-19 Aventis Behring GmbH Erhöhung der Expression von Faktor VIII durch Insertion von spleissbaren Nukleotidsequenzen in Faktor VIII cDNA

Also Published As

Publication number Publication date
PT1673391E (pt) 2009-03-18
EP1673391B1 (de) 2008-12-10
SI1673391T1 (sl) 2009-06-30
IL174645A0 (en) 2006-08-20
DK1673391T3 (da) 2009-04-06
AU2004283833A1 (en) 2005-05-06
EP1673391A1 (de) 2006-06-28
CA2541280A1 (en) 2005-05-06
DE602004018349D1 (de) 2009-01-22
BRPI0415296A (pt) 2006-12-26
JP4804356B2 (ja) 2011-11-02
PL1673391T3 (pl) 2009-06-30
ES2319198T3 (es) 2009-05-05
JP2007537713A (ja) 2007-12-27
WO2005040213A1 (en) 2005-05-06
US20080312143A1 (en) 2008-12-18

Similar Documents

Publication Publication Date Title
DE60327786D1 (de) Kdr-peptide und diese enthaltende impfstoffe
DK1781782T3 (da) Modificerede vitamin K-afhængige polypeptider
MXPA03010079A (es) Formulaciones de oxicodona de administracion una vez al dia.
WO2006128668A3 (en) Coagulation factor x polypeptides with modified activation properties
DE69434447D1 (de) Für die gentherapie verwendbare plasmide
SI1675956T1 (sl) Minimalno zaporedje dna, ki deluje kot izolirni element kromatina in njegova uporaba pri ekspresiji proteinov
DE60230456D1 (de) Faktor-viii-polypeptide auf hohem expressionsnivea und verwendungsverfahren
ATE333520T1 (de) Neuartige polynukleotide und polypeptide des ifnalpha-21 gens
DE602004018349D1 (de) MODIFIZIERTE cDNA FÜR HOHE EXPRESSIONSNIVEAUS VON FAKTOR VIII UND DESSEN DERIVATEN
ATE532861T1 (de) Expressionsvektor
AP2000001999A0 (en) Gene therapy method.
DE60120187D1 (de) Verkürztes bard1 protein und dessen diagnostische und therapeutische anwendungen
DE60310708D1 (de) In vivo stabilsierung von plasmiden
DE69912118D1 (de) Entomopoxvirus vektor zur abgabe und expression von dns heterologen in vertebratenzellen
WO2002034882A3 (en) Genes regulating programmed cell death
DE10394174D2 (de) Peptide mit hohem Cysteingehalt
DE60024442D1 (de) Verwendung von viralen vektoren und geladenen molekülen für die gentherapie
SE0101317D0 (sv) Protein cluster v
WO2002077193A8 (en) Isolated human ras-like proteins, nucleic acid molecules encoding these human ras-like proteins, and uses thereof
WO2002059151A3 (en) Isolated human g-protein coupled receptors, nucleic acid molecules encoding human gpcr proteins, and uses thereof

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1673391

Country of ref document: EP